Mamotest Secures $1.5M Investment to Scale AI-Driven Breast Cancer Care

How can life-saving breast cancer diagnostics reach underserved populations across four countries and beyond? Mamotest, a Hub71 startup from Cohort 15 (2024), is proving how innovation and purpose can transform healthcare on a global scale.
In December, Mamotest secured a $1.5 million investment from Philips Foundation Impact Investments, marking the foundation's first foray into supporting a Latin American-led health tech company. This milestone brings Mamotest's total funding to $7 million, with previous investments from healthcare giants like Merck Sharp & Dohme (MSD) and Johnson & Johnson Impact Ventures.
The funding boost is set to supercharge Mamotest's mission of democratizing access to breast cancer care through AI and real-world data. Powered by BolderAi, their proprietary technology, Mamotest is reshaping diagnostics and improving patient outcomes. By streamlining radiologists' workflows, the technology enhances efficiency, shortens patient wait times, and improves diagnostic accuracy. This streamlined approach ensures no patient is left behind, with Mamotest's end-to-end model guaranteeing 100% traceability of the patient journey - from diagnosis to treatment.
Having commenced operations in Argentina, Mexico, Brazil, and Spain, Mamotest has already made a significant impact:
- 750,000+ women reached
- 4,000 health professionals engaged
- 87% rate of timely treatment for diagnosed breast cancer cases
As Mamotest continues to expand, its innovative approach serves as a powerful example of how AI-driven solutions can revolutionize patient care, drive transformative change, and save lives globally.
A Vision Backed by Global Leaders
Guillermo Pepe, Mamotest's CEO and a recent recipient of the Frost & Sullivan Visionary Leadership Award, emphasized the importance of strategic partners like Philips Foundation Impact Investments. He stated: "Their belief in our vision validates the global impact of our work. This partnership allows us to develop innovative AI-driven solutions that redefine healthcare systems and extend quality care to millions."
For Philips Foundation, the investment reflects its commitment to advancing global health equity. Margot Cooijmans, Director of the Philips Foundation, noted: "Mamotest's work transforms lives by bringing essential breast cancer diagnostics to underserved communities. This is exactly the kind of innovation we aim to amplify."
Scaling with Hub71's Support
Since joining Hub71's Cohort 15 in 2024, Mamotest has tapped into a dynamic ecosystem designed to fast-track startups with transformative potential. Through mentorship, networking, and funding opportunities, Hub71 has played a critical role in supporting the company's growth and international expansion.
The Road Ahead
With its latest investment, Mamotest is poised to amplify its impact across Latin America and Europe, scaling its AI-driven solutions to tackle one of healthcare's most pressing challenges: equitable access to life-saving diagnostics and treatments.
As Mamotest continues to innovate, it offers a blueprint for what's possible when cutting-edge technology meets a relentless commitment to improving lives.